BACKGROUND: The association of subclinical vascular disease and early declines in kidney function has not been well studied. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Multi-Ethnic Study of Atherosclerosis (MESA) participants with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m(2) with follow-up of 5 years. PREDICTORS: Pulse pressure, small (SAE) and large arterial elasticity (LAE), and flow-mediated dilation. OUTCOMES: Kidney function decline. MEASUREMENTS: SAE and LAE were measured by pulse contour analysis of the radial artery. Kidney function was assessed by eGFR based on serum creatinine (eGFR(SCr)) and cystatin C (eGFR(SCysC)). RESULTS: For 4,853 adults, higher pulse pressure and lower SAE and LAE had independent and linear associations with faster rates of kidney function decline. Compared with persons with pulse pressure of 40-50 mm Hg, eGFR(SCysC) declines were 0.29 (P = 0.006), 0.56 (P < 0.001), and 0.91 (P < 0.001) mL/min/1.73 m(2)/y faster in persons with pulse pressure of 50-60, 60-70, and >70 mm Hg, respectively. Compared with the highest quartile of SAE (most elastic), eGFR(SCysC) declines were 0.26 (P = 0.009), 0.35 (P = 0.001), and 0.70 (P < 0.001) mL/min/1.73 m(2)/y faster for the second, third, and fourth quartiles, respectively. For LAE, compared with the highest quartile, eGFR(SCysC) declines were 0.28 (P = 0.004), 0.58 (P < 0.001), and 0.83 (P < 0.001) mL/min/1.73 m(2)/y faster for each decreasing quartile of LAE. Findings were similar for eGFR(SCr). In contrast, for 2,997 adults with flow-mediated dilation and kidney function measures, flow-mediated dilation was not associated significantly with kidney function decline. For every 1-standard deviation greater flow-mediated dilation, eGFR(SCysC) and eGFR(SCr) changed by 0.05 (P = 0.3) and 0.06 mL/min/1.73 m(2)/y (P = 0.04), respectively. LIMITATIONS: We had no direct measure of GFR, in common with nearly all large population-based studies. CONCLUSIONS: Higher pulse pressure and lower arterial elasticity, but not flow-mediated dilation, were associated linearly and independently with faster kidney function decline in persons with eGFR ≥60 mL/min/1.73 m(2). Future studies should investigate whether treatments to decrease the stiffness of large and small arteries may slow the rate of kidney function loss.
BACKGROUND: The association of subclinical vascular disease and early declines in kidney function has not been well studied. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Multi-Ethnic Study of Atherosclerosis (MESA) participants with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m(2) with follow-up of 5 years. PREDICTORS: Pulse pressure, small (SAE) and large arterial elasticity (LAE), and flow-mediated dilation. OUTCOMES: Kidney function decline. MEASUREMENTS: SAE and LAE were measured by pulse contour analysis of the radial artery. Kidney function was assessed by eGFR based on serum creatinine (eGFR(SCr)) and cystatin C (eGFR(SCysC)). RESULTS: For 4,853 adults, higher pulse pressure and lower SAE and LAE had independent and linear associations with faster rates of kidney function decline. Compared with persons with pulse pressure of 40-50 mm Hg, eGFR(SCysC) declines were 0.29 (P = 0.006), 0.56 (P < 0.001), and 0.91 (P < 0.001) mL/min/1.73 m(2)/y faster in persons with pulse pressure of 50-60, 60-70, and >70 mm Hg, respectively. Compared with the highest quartile of SAE (most elastic), eGFR(SCysC) declines were 0.26 (P = 0.009), 0.35 (P = 0.001), and 0.70 (P < 0.001) mL/min/1.73 m(2)/y faster for the second, third, and fourth quartiles, respectively. For LAE, compared with the highest quartile, eGFR(SCysC) declines were 0.28 (P = 0.004), 0.58 (P < 0.001), and 0.83 (P < 0.001) mL/min/1.73 m(2)/y faster for each decreasing quartile of LAE. Findings were similar for eGFR(SCr). In contrast, for 2,997 adults with flow-mediated dilation and kidney function measures, flow-mediated dilation was not associated significantly with kidney function decline. For every 1-standard deviation greater flow-mediated dilation, eGFR(SCysC) and eGFR(SCr) changed by 0.05 (P = 0.3) and 0.06 mL/min/1.73 m(2)/y (P = 0.04), respectively. LIMITATIONS: We had no direct measure of GFR, in common with nearly all large population-based studies. CONCLUSIONS: Higher pulse pressure and lower arterial elasticity, but not flow-mediated dilation, were associated linearly and independently with faster kidney function decline in persons with eGFR ≥60 mL/min/1.73 m(2). Future studies should investigate whether treatments to decrease the stiffness of large and small arteries may slow the rate of kidney function loss.
Authors: A Benetos; M Zureik; J Morcet; F Thomas; K Bean; M Safar; P Ducimetière; L Guize Journal: J Am Coll Cardiol Date: 2000-03-01 Impact factor: 24.094
Authors: Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: E J Kim; C G Park; J S Park; S Y Suh; C U Choi; J W Kim; S H Kim; H E Lim; S W Rha; H S Seo; D J Oh Journal: J Hum Hypertens Date: 2006-11-30 Impact factor: 3.012
Authors: Mengli Tong; Juan Jesús Carrero; A Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Anders Alvestrand; Peter Stenvinkel; Bengt Lindholm; Mohamed E Suliman Journal: Clin J Am Soc Nephrol Date: 2007-08-16 Impact factor: 8.237
Authors: Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez Journal: J Hypertens Date: 2015-05 Impact factor: 4.844
Authors: Otto A Sanchez; Daniel A Duprez; Lori B Daniels; Alan S Maisel; James D Otvos; Carmen A Peralta; João A Lima; Hossein Bahrami; David R Jacobs Journal: Metabolism Date: 2015-04-15 Impact factor: 8.694
Authors: O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs Journal: Diabetes Metab Date: 2015-06-03 Impact factor: 6.041
Authors: Katherine H Michener; Gary F Mitchell; Farzad Noubary; Naya Huang; Tamara Harris; Margret B Andresdottir; Runolfur Palsson; Vilmundur Gudnason; Andrew S Levey Journal: Am J Nephrol Date: 2015-06-06 Impact factor: 3.754
Authors: Bjørn O Eriksen; Runolfur Palsson; Natalie Ebert; Toralf Melsom; Markus van der Giet; Vilmundur Gudnason; Olafur S Indridason; Lesley A Inker; Trond G Jenssen; Andrew S Levey; Marit D Solbu; Hocine Tighiouart; Elke Schaeffner Journal: J Am Soc Nephrol Date: 2020-06-04 Impact factor: 10.121
Authors: Samuel Headley; Michael Germain; Richard Wood; Jyovani Joubert; Charles Milch; Elizabeth Evans; Anthony Poindexter; Allen Cornelius; Britton Brewer; Linda S Pescatello; Beth Parker Journal: Am J Kidney Dis Date: 2014-04-26 Impact factor: 8.860
Authors: Daichi Shimbo; Steven Shea; Robyn L McClelland; Anthony J Viera; Devin Mann; Jonathan Newman; Joao Lima; Joseph F Polak; Bruce M Psaty; Paul Muntner Journal: Am J Hypertens Date: 2013-03-28 Impact factor: 2.689